Proton pump inhibitor-induced neutropenia: Possible cross-reactivity between omeprazole and pantoprazole

Clinical Drug Investigation

Volumn 30, Issue 8, 2010, Pages 559-563

  Gouraud, Aurore ^a   Vochelle, Véronique ^b   Descotes, Jacques ^a   Vial, Thierry ^a  

^a University Hospital   (France)

^b Hepatology and Gastro Enterology Department   (France)

Author keywords

Neutropenia; Omeprazole, therapeutic use; Pantoprazole, therapeutic use; Proton pump inhibitors, therapeutic use

Indexed keywords

OMEPRAZOLE; PANTOPRAZOLE; RANITIDINE; SUCRALFATE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; PROTON PUMP INHIBITOR;

ADULT; ALCOHOLISM; ANAMNESIS; ARTICLE; BARRETT ESOPHAGUS; BLOOD CELL COUNT; CASE REPORT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GASTRITIS; GASTROSCOPY; HIATUS HERNIA; HUMAN; LABORATORY TEST; MALE; NEUTRON THERAPY; NEUTROPENIA; PRIORITY JOURNAL; SIDE EFFECT; CHEMICALLY INDUCED; CROSS REACTION; IMMUNOLOGY; MIDDLE AGED;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; CROSS REACTIONS; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; OMEPRAZOLE; PROTON PUMP INHIBITORS;

EID: 77954209573     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11537230-000000000-00000     Document Type: Article

References (21)

1. IMS Health Report. Global sales and prescription information 2007 [online]. Available from URL: http://www.imshealth.com/portal/site/imshealth/ menuitem [Accessed 2009 Jun 24]
2. Holt TL, Coombes ID, Pillans PI, et al. Neutropenia associated with omeprazole. Med J Aust 1999; 170: 141-142
3. Ottervanger JP, Stricker BH, Kappelle JW, et al. Omeprazole-associated agranulocytosis. Eur J Haematol 1995; 54: 279-280
4. Gabutti L, Stoller R, Vogt B. Omeprazole-induced agranulocytosis in a kidney transplant recipient. Nephrol Dial Transplant 1999; 14: 523-524
5. Losec® Capsules 10 mg, 20 mg and 40 mg: summary of product characteristics. Astra Zeneca UK. Last revision: 21 Jul 2008 [online]. Available from URL: http://www.medicines.org.uk [Accessed 2010 May 14]
6. Pantoloc Control 20mg gastro-resistant tablets: summary of product characteristics. Nycomed UK Ltd. Last revision: 23 Mar 2010 [online]. Available from URL: http://www.medicines.org.uk [Accessed 2010 May 14]
7. Pariet 10mgand 20 mg: summary of product characteristics. Eisai Ltd. Last revision 28 Apr 2010 [online]. Available from URL http://www.medicines.org.uk [Accessed 2010 May 14]
8. Nexium® 20 mg and 40 mg tablets: summary of product characteristics. Astra Zeneca UK. Last revision: 22 Oct 2009 [online]. Available from URL: http://www.medicines.org.uk [Accessed 2010 May 14]
9. Lansoprazole 15mg gastro-resistant capsules: summary of product characteristics. Astra Winthrop Pharmaceuticals UK Ltd. Last revision: 30 Apr 2010 [online]. Available from URL: http://www.medicines.org.uk [Accessed 2010 May 14]
10. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42 Suppl. 3: S1-201
11. Tavassoli N, Duchayne E, Sadaba B, et al. Detection and incidence of drug-induced agranulocytosis in hospital: a prospective analysis from laboratory signals. Eur J Clin Pharmacol 2007; 63: 221-228
12. Andres E, Maloisel F. Idiosyncratic drug-induced agranulocytosis or acute neutropenia. Curr Opin Hematol 2008; 15: 15-21
13. Ramos-Casals M, Garc?a-Carrasco M, Lopez-Medrano F, et al. Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 35 cases. Medicine (Baltimore) 2003; 82: 87-96
14. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245 (Pubitemid 12149145)
15. Bhatt V, Saleem A. Review: drug-induced neutropenia. Pathophysiology, clinical features, and management. Ann Clin Lab Sci 2004; 34: 131-137
16. Pisciotta AV. Drug-induced agranulocytosis: peripheral destruction of polymorphonuclear leukocytes and their marrow precursors. Blood Rev 1990; 4: 226-237
17. Palmblad J, Papadaki HA, Eliopoulos G. Acute and chronic neutropenias: what is new? J Intern Med 2001; 250: 476-491
18. Castot A, Bidault I, Dahan R, et al. Evaluation of unexpected and toxic effects of omeprazole (Mopral) reported to the regional centers of pharmacovigilance during the first 22 postmarketing months. Therapie 1993; 48: 469-474
19. Lobera T, Navarro B, Del Pozo MD, et al. Nine cases of omeprazole allergy: cross-reactivity between proton pump inhibitors. J Investig Allergol Clin Immunol 2009; 19: 57-60
20. Vovolis V, Koutsostathis N, Stefanaki E. IgE-mediated anaphylaxis to proton pump inhibitors-cross-reacting study. Allergy 2008; 63: 1251-1252
21. Garrido Fernandez S, Cumplido JA, Rabano A, et al. Allergy to proton pump inhibitors: diagnosis and assessment of cross-reactivity. J Investig Allergol Clin Immunol 2008; 18: 140-141